Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Robust methylation-based classification of brain tumors using nanopore sequencing

View ORCID ProfileLuis P. Kuschel, Jürgen Hench, Stephan Frank, Ivana Bratic Hench, Elodie Girard, Maud Blanluet, Julien Masliah-Planchon, Martin Misch, Julia Onken, Marcus Czabanka, Philipp Karau, Naveed Ishaque, Elisabeth G. Hain, Frank Heppner, Ahmed Idbaih, Nikolaus Behr, Christoph Harms, David Capper, Philipp Euskirchen
doi: https://doi.org/10.1101/2021.03.06.21252627
Luis P. Kuschel
1Charité - Universitätsmedizin Berlin, Germany, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Department of Neurology with Experimental Neurology, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Luis P. Kuschel
Jürgen Hench
2Department of Pathology, Universitätsspital Basel, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephan Frank
2Department of Pathology, Universitätsspital Basel, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ivana Bratic Hench
2Department of Pathology, Universitätsspital Basel, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elodie Girard
3Institut Curie, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maud Blanluet
3Institut Curie, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julien Masliah-Planchon
3Institut Curie, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Misch
4Charité - Universitätsmedizin Berlin, Germany, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Department of Neurosurgery, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julia Onken
4Charité - Universitätsmedizin Berlin, Germany, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Department of Neurosurgery, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcus Czabanka
4Charité - Universitätsmedizin Berlin, Germany, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Department of Neurosurgery, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philipp Karau
5Center for Digital Health, Berlin Institute of Health (BIH) and Charité - Universitätsmedizin Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Naveed Ishaque
5Center for Digital Health, Berlin Institute of Health (BIH) and Charité - Universitätsmedizin Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elisabeth G. Hain
6Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Department of Neuropathology, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frank Heppner
6Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Department of Neuropathology, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ahmed Idbaih
7Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, F-75013, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nikolaus Behr
1Charité - Universitätsmedizin Berlin, Germany, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Department of Neurology with Experimental Neurology, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christoph Harms
1Charité - Universitätsmedizin Berlin, Germany, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Department of Neurology with Experimental Neurology, Berlin, Germany
9Center for Stroke Research, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Capper
6Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Department of Neuropathology, Berlin, Germany
8German Cancer Consortium (DKTK), Partner Site Berlin, German Cancer Research Center (DKFZ), Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philipp Euskirchen
1Charité - Universitätsmedizin Berlin, Germany, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Department of Neurology with Experimental Neurology, Berlin, Germany
8German Cancer Consortium (DKTK), Partner Site Berlin, German Cancer Research Center (DKFZ), Heidelberg, Germany
9Center for Stroke Research, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: philipp.euskirchen@charite.de
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

DNA methylation-based classification of cancer provides a comprehensive molecular approach to diagnose tumors. In fact, DNA methylation profiling of human brain tumors already profoundly impacts clinical neuro-oncology. However, current implementations using hybridization microarrays are time-consuming and costly. We recently reported on shallow nanopore whole-genome sequencing for rapid and cost-effective generation of genome-wide 5-methylcytosine profiles as input to supervised classification using random forests complemented by a medium-resolution copy number profile derived from the same raw data. Here, we demonstrate that this approach allows to discriminate a wide spectrum of primary brain tumors using public reference data of 82 distinct tumor entities. We developed a pseudo-probability score as a confidence score for interpretation in a clinical context. Using bootstrap sampling in a discovery cohort of N = 56 cases, we find that a minimum set of 1,000 random CpG features is sufficient for high-confidence classification by ad hoc random forests for most cases and demonstrate robustness across laboratories with matching results in 13/13 cases. When applying the confidence score threshold to an independent validation series (N = 111), the method demonstrated 100% specificity for the remaining 93 cases. In a prospective benchmarking (N = 15), median time to results was 21.1 hours. In conclusion, nanopore sequencing allows robust and rapid methylation-based classification across the full spectrum of brain tumors. The integrated confidence score facilitates possible clinical implementation, while requiring further prospective evaluation.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

U1111-1239-3456

Funding Statement

The study was funded by the Brain Tumour Charity (UK) - GN-000694

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The local ethics committee (Charité Universitätsmedizin Berlin, Berlin, Germany; EA2/041/18) approved generation of prospective data in the context of this study.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Conflicts of interest The authors declare no conflicts of interest.

Data Availability

The current nanoDx classification and analysis pipeline https://gitlab.com/pesk/nanoDx (version v.0.2.1 was used for preprocessing of all sequencing data) and the source code for the outlined RF implementation and to reproduce all analyses and figures in this manuscript https://gitlab.com/pesk/nanoBenchmark will be publicly available upon publication. Raw sequencing data from the discovery cohort will be deposited at the European Genome-phenome archive (accession tba). Methylation microarray raw data and methylation calls from the validation cohort will be deposited at ArrayExpress (accession tba).

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted March 08, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Robust methylation-based classification of brain tumors using nanopore sequencing
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Robust methylation-based classification of brain tumors using nanopore sequencing
Luis P. Kuschel, Jürgen Hench, Stephan Frank, Ivana Bratic Hench, Elodie Girard, Maud Blanluet, Julien Masliah-Planchon, Martin Misch, Julia Onken, Marcus Czabanka, Philipp Karau, Naveed Ishaque, Elisabeth G. Hain, Frank Heppner, Ahmed Idbaih, Nikolaus Behr, Christoph Harms, David Capper, Philipp Euskirchen
medRxiv 2021.03.06.21252627; doi: https://doi.org/10.1101/2021.03.06.21252627
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Robust methylation-based classification of brain tumors using nanopore sequencing
Luis P. Kuschel, Jürgen Hench, Stephan Frank, Ivana Bratic Hench, Elodie Girard, Maud Blanluet, Julien Masliah-Planchon, Martin Misch, Julia Onken, Marcus Czabanka, Philipp Karau, Naveed Ishaque, Elisabeth G. Hain, Frank Heppner, Ahmed Idbaih, Nikolaus Behr, Christoph Harms, David Capper, Philipp Euskirchen
medRxiv 2021.03.06.21252627; doi: https://doi.org/10.1101/2021.03.06.21252627

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Oncology
Subject Areas
All Articles
  • Addiction Medicine (228)
  • Allergy and Immunology (506)
  • Anesthesia (110)
  • Cardiovascular Medicine (1244)
  • Dentistry and Oral Medicine (206)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (532)
  • Epidemiology (10027)
  • Forensic Medicine (5)
  • Gastroenterology (500)
  • Genetic and Genomic Medicine (2462)
  • Geriatric Medicine (238)
  • Health Economics (479)
  • Health Informatics (1645)
  • Health Policy (753)
  • Health Systems and Quality Improvement (636)
  • Hematology (250)
  • HIV/AIDS (535)
  • Infectious Diseases (except HIV/AIDS) (11871)
  • Intensive Care and Critical Care Medicine (626)
  • Medical Education (253)
  • Medical Ethics (75)
  • Nephrology (268)
  • Neurology (2289)
  • Nursing (139)
  • Nutrition (352)
  • Obstetrics and Gynecology (454)
  • Occupational and Environmental Health (537)
  • Oncology (1248)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (158)
  • Palliative Medicine (50)
  • Pathology (325)
  • Pediatrics (733)
  • Pharmacology and Therapeutics (314)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2281)
  • Public and Global Health (4840)
  • Radiology and Imaging (838)
  • Rehabilitation Medicine and Physical Therapy (492)
  • Respiratory Medicine (651)
  • Rheumatology (286)
  • Sexual and Reproductive Health (240)
  • Sports Medicine (227)
  • Surgery (268)
  • Toxicology (44)
  • Transplantation (125)
  • Urology (99)